Renal Disease Clinical Trial
Official title:
Comparison of Medication Adherence Between Once Daily Tacrolimus (Advagraf®) and Twice Daily Tacrolimus (Prograf®) Administration in Stable Renal Transplant Recipients - a Randomized Study
A critical aspect of real-world functioning following kidney transplantation involves how
adherent individuals are to their medication regimens. Regardless of the possible dangers of
failing to adhere to anti-rejection medications, such as increased graft rejection, studies
have reported rates of non-adherence at almost 50% following renal transplant.
The Cognitive Aging Laboratory under the direction of Dr. Wendy Thornton, at Simon Fraser
University, has previously identified relationships between several potentially important
cognitive and psychosocial variables, and self-reported medication adherence in renal
transplant recipients, including depressive symptoms, as well as everyday and traditional
cognitive functioning [4]. The possibility that changes in dosing regimens for a given
medication may have an additional impact on medication adherence presents an important issue
worth further exploration.
The current study will allow for more thorough delineation of the roles of psychosocial and
cognitive predictors of adherence with state-of-the-art monitoring techniques. In addition,
the investigators will assess whether different dosing formulations of tacrolimus impact
adherence behaviors in renal transplant recipients.
The proposed research has two primary aims to examine:
1. To examine the role of cognitive and psychosocial variables in predicting medication
adherence in renal transplant recipients.
2. To examine whether different formulations of tacrolimus (once per day dosing versus
twice per day dosing) will impact medication adherence in renal transplant recipients.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
Completed |
NCT01545531 -
Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance
|
N/A | |
Recruiting |
NCT05700903 -
Contributions to Hypertension With Androgen Deprivation Therapy
|
Phase 4 | |
Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
Withdrawn |
NCT04556721 -
A Pharmacokinetic Study of Sugammadex in Dialysis Patients
|
Phase 1 | |
Active, not recruiting |
NCT04078750 -
PLATO - Medication Adherence in Transplant Recipients
|
N/A | |
Not yet recruiting |
NCT04531124 -
Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives
|
||
Completed |
NCT03107195 -
Biokinetics Study of Tc-99m DMSA in Pediatric Molecular Imaging
|
||
Completed |
NCT03463148 -
Validation of a Sensor for Non-Invasive Measurements
|
||
Recruiting |
NCT03578523 -
Renal MR Feasibility in Renal Disease
|
||
Withdrawn |
NCT01468259 -
A Multi-Center, Open-Label Study
|
Phase 1 | |
Completed |
NCT01256983 -
Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation
|
Phase 0 | |
Completed |
NCT06070337 -
H-Guard Pilot Safety Evaluation in Haemodialysis Patients
|
N/A | |
Completed |
NCT05593211 -
Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures
|
N/A | |
Completed |
NCT03242343 -
VasQ External Support for Arteriovenous Fistula
|
N/A | |
Completed |
NCT03438123 -
Data Collection Study for the Spectrum Dynamics Multi-purpose CZT SPECT Camera
|
N/A | |
Recruiting |
NCT05443321 -
Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes
|
N/A | |
Completed |
NCT04407182 -
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06419270 -
Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
|
||
Not yet recruiting |
NCT04834089 -
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
|
Phase 1/Phase 2 |